Compare SPXC & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPXC | HALO |
|---|---|---|
| Founded | 1912 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5B | 8.5B |
| IPO Year | N/A | N/A |
| Metric | SPXC | HALO |
|---|---|---|
| Price | $212.75 | $76.19 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 12 |
| Target Price | ★ $214.14 | $76.42 |
| AVG Volume (30 Days) | 444.0K | ★ 1.9M |
| Earning Date | 02-24-2026 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 26.00 | ★ 56.68 |
| EPS | 4.69 | ★ 4.74 |
| Revenue | ★ $2,161,500,000.00 | $1,242,852,000.00 |
| Revenue This Year | $16.13 | $34.54 |
| Revenue Next Year | $9.07 | $26.28 |
| P/E Ratio | $45.39 | ★ $15.72 |
| Revenue Growth | 12.60 | ★ 31.19 |
| 52 Week Low | $115.00 | $47.50 |
| 52 Week High | $233.71 | $79.50 |
| Indicator | SPXC | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 51.51 | 65.91 |
| Support Level | $207.75 | $71.23 |
| Resistance Level | $215.75 | $74.48 |
| Average True Range (ATR) | 6.40 | 2.43 |
| MACD | -0.34 | 0.30 |
| Stochastic Oscillator | 30.11 | 92.04 |
SPX Technologies Inc supplies engineered heating, ventilation, and air conditioning, or HVAC, products, as well as detection and measurement technologies and power equipment. The company through two reportable segments. The HVAC segment which generates the majority of the revenue for the company, designs, manufactures, installs, and services cooling products, as well as heating and ventilation products. The detection and measurement technologies segment designs, manufactures, and installs underground pipe and cable locators and inspection equipment, bus-fare collection systems, and others. Geographically, the company has its operations in the United States, Canada, China, the United Kingdom, and Others.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.